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COSTS OF HOSPITALIZATION FOR HEMATOPOIETIC CELL TRANSPLAN-
TATION (HCT) IN THE UNITED STATES (U.S.): A PILOT STUDY USING
A LARGE NATIONAL COMMERCIAL PAYOR DATABASE
Majhail, N.S.1,2, Mau, L.-W.3, Denzen, E.1, Arneson, T.J.3 1National
Marrow Donor Program, Minneapolis, MN; 2Center for International
Blood andMarrow Transplant Research,Minneapolis,MN; 3Chronic Dis-
ease Research Group, Minneapolis, MN
HCT is a resource-intense and expensive procedure. Single insti-
tution studies have described costs of HCT; however, costs from the
national perspective are not well known. We used a large US com-
mercial payor database (Thomson Reuters MarketScan) to assemble
a cohort of patients who received HCT. The aim of our study was to
evaluate the feasibility of using this database to investigate costs over
the first 100 days after transplantation among adult and pediatric re-
cipients of allogeneic and autologous transplantation. Here we pres-
ent results for HCT hospitalization. MarketScan is a claims and
encounters database that includes specific health services records
for employees and their dependents in a selection of large employers,
health plans and government organizations. Claims and encounter
data are linked to detailed patient demographic and enrollment in-
formation across sites and types of providers. For our study, we
used ICD-9 diagnosis and procedure codes to identify HCT recipi-
ents. We identified 3816 patients who received HCT from 2007 to
2009; these patients accounted for 4026 HCT hospitalizations.
Among these, 41% were allogeneic HCT, 49% were autologous
HCT, and the type of HCTwas not specified in 9%. Themost com-
mon indication for allogeneic HCT was acute myeloid leukemia
(20%), and for autologous HCT multiple myeloma was most com-
mon (40%). The mean length of hospital stay was 30 (SD 20) days
for allogeneic and 19 (SD 11) days for autologous HCT recipients.
The mean age for allogeneic HCT recipients was 43 (SD 18) years,
while it was 51 (SD 16) years for autologous HCT recipients
(P\0.01). The mean costs of HCT hospitalizations was $196,307
for allogeneic and $96,153 for autologous HCT recipients. Our
study highlights the feasibility of using the MarketScan commercial
payor database to identify HCT recipients and to study costs of
HCT in the U.S. Ongoing analyses will describe total inpatient
and outpatient costs within the first 100 days of HCT and variations
in these costs by age group and geographic region.294
NOROVIRUS GASTROENTERITIS – AN EMERGING PATHOGEN IN PEDIAT-
RIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RECIPIENTS
Ozdemir, N., Davies, S.M., Filipovich, A.H., Bleesing, J.J., Jodele, S.,
Grimley,M.S.,Marsh, R.A.,Myers, K.C.,Mehta, P.A. Cincinnati Child-
ren’s Hospital Medical Center, Cincinnati, OH
Background: Norovirus (family of the Calciviridae) infection is
a common cause of acute gastroenteritis, however, data on norovirus
infection is limited in immunocompromised patients. Here we re-
port our single center experience with norovirus infection in 12 pe-
diatric HSCT patients.
Methods: Patient demographics and transplant characteristics are
described in Table 1.
Table 1. PatientDemographics andTransplantCharacteristics
Sex/Age Donor Type of Concurrent
Patient #S314(years) Diagnosis type conditioning GVHDGut Skin Liver
1 M/1.0 HLH URD RIC + + -
2 F/1.6 SCID URD RIC - + -
3 M/9.6 Autoimmune
neutropenia
URD RIC - - -4 M/0.5 HLH MSD RIC - - -
5 M/22.1 MDS MSD MAC - - -
6 F/2.1 Ligase IV deficiency URD RIC - - -(Continued )Table 1. (Continued )Patient #
Sex/Age
(years) Diagnosis
Donor
type cType of
onditioning
Concurrent
GVHD7 M/0.7 WAS UCB MAC - + -
8 M/18.2 XLP URD RIC + - -
9 M/5.8 SCID URD RIC - + -
10 F/11.4 CML URD MAC - - -
11 F/8.2 FA URD MAC - + -
12 M/1.7 HLH URD RIC - - -RIC: reduced-intensity conditioning, MAC: myeloablative conditioning;
HLH: hemophagocytic lymphohistiocytosis; SCID: severe combined im-
munodeficiency; MDS; myelodysplastic syndrome; WAS: Wiskott-Al-
drich syndrome; XLP: X-linked lymphoproliferative syndrome; CML:
Chronic myelogenous leukemia; FA: Fanconi anemia; URD: unrelated
donor; MSD: matched sibling donor; UCB: unrelated cord blood;
GVHD: graft versus host disease
Results: Twelve patients presented between January 2009-Septem-
ber 2011, with diarrhea. Most patients (9/12) also had significant
nausea and vomiting. At initial presentation, patients had diarrhea
for a median of 31 days (range: 3-72) and nausea/vomiting for 5
days (range: 1-30). One or more complications such as hypotension,
hypovolemic shock, protein losing enteropathy, pneumatosis intesti-
nalis occured in 9 patients, with 3 requiring transfer to intensive care
unit for the same. All 12 patients had positive stool PCR. Eight pa-
tients had prolonged PCR positivity for more than 3 months, and
one of them had intermittent shedding. These patients also had
a prolonged clinical course with persistent or intermittent diarrhea,
abdominal discomfort, nausea and vomiting. In total, 11 patients had
significant weight loss and required supplemental intravenous/en-
teral nutritional support. Five patients hadC. difficile and 4 had stool
adenovirus positivity around the time of norovirus infection, how-
ever, they remained symptomatic despite clearing C. difficile and ad-
enovirus in stool, correlating with persistent positive norovirus
PCRs. All 12 patients were treated with intravenous immunoglobu-
lin (IVIG) and 4 patients with severe or chronic course received 14
day course of nitazoxinide. Three out of 4 responded in terms of im-
proved/resolved symptoms. In patients treated only with IVIG sup-
port, 7/8 cleared acute symptoms, but only two who became PCR
negative, clearly had resolution of symptoms. Remaining 5 although
improved initially, continued to have low grade chronic symptoms
correlating with their PCR positivity.
Conclusion: Norovirus can have a prolonged chronic or relapsing
course with significant morbidity and potential mortality in children
undergoing HSCT. Treatment with IVIG and/or nitazoxinide ap-
pears to be effective in shortening the duration of symptoms. In ad-
dition, in our small cohort, achievement of PCR negativity seems to
correlate with resolution of illness. Prospective studies including
large number of patients are warranted to better understand norovi-
rus disease in HSCT setting.295
HUMAN BIOMARKER DISCOVERY AND PREDICTIVE MODELS OF DISEASE
PROGRESSION AND RESPONSE TO THERAPY FOR IDIOPATHIC PNEUMO-
NIA SYNDROME
Schlatzer, D.M.1, Eudes Dazard, J.1, Tomecheko, S.E.1, Yanik, G.2,
Ho, V.3, Chance, M.R.1, Cooke, K.R.4 1Case Western Reserve University,
Cleveland, OH; 2University of Michigan, Ann Arbor, MI; 3Dana Farber
Cancer Institute, Boston, MA; 4Case Western Reserve University, Cleve-
land, OH
Idiopathic pneumonia syndrome (IPS) is a frequently fatal compli-
cation following allogeneic BMT (allo-BMT). Experimental models
have demonstrated a critical role for TNFa in the development of
IPS, but mechanisms responsible for human disease are poorly char-
acterized. Using samples collected from a pilot trial using etanercept
(Enbrel ) for IPS, we performed two separate label-free, proteo-
mics experiments utilizing liquid chromatography and mass spec-
trometry to define inflammatory pathways contributing to the
clinical syndrome. Allo-BMT recipients without complications
Poster Session I S315served as controls. Using samples from over 20 patients in four
groups, we first conducted a discovery study to identify peptide vari-
ables that were significant across disease development (control vs.
IPS) and time (day 0 vs. day of Dx or day 14 for controls). This re-
vealed a set of 81 IPS-associated proteins that were verified by a num-
ber of methods, analyzed by ingenuity pathway analysis (IPA) and
mapped to relevant immune pathways. IPA underscored a significant
contribution of the acute phase response (TNFa / IL-6) signaling
pathway during disease progression and revealed striking similarities
between inflammation engendered during IPS in humans and mice.
In the second verification analysis, we used only samples collected on
day 0 from a larger cohort of patients to identify proteins that were
effective variables for patient stratification. Identified peptides were
subjected to predictive model building using the Ishwaran&Rao ap-
proach, which identified a set of robust plasma proteomic markers
that could 1) predict the development of IPS, and 2) identify individ-
uals who would ultimately respond to etanercept therapy. Analysis
also revealed a number of novel proteins including attractin, lumican
and LBP (the expression of which was verified by ELISA) that were
significant in the discovery analysis and classifiers for disease devel-
opment and or response to therapy. In sum, data generated in this
translational research endeavor confirm previous clinical and exper-
imental observations, provide new insights into the pathophysiology
of IPS and identify a set of robust markers predictive for disease pro-
gression and response to therapy. As anti-TNF therapies are being
developed as treatment for GVHD and other immune-mediated dis-
orders, these results uncover a set of robust markers for patient strat-
ification as a basis for individualized therapy that is ripe for further
development.296
CMX001 AS THERAPY FOR SEVERE ADENOVIRUS INFECTIONS IN IMMU-
NOCOMPROMISED PEDIATRIC PATIENTS: SINGLE EXPERIENCE IN 5 PA-
TIENTS
Grimley, M.S.1, Marsh, R.A.1, Bleesing, J.J.1, Mehta, P.A.1,
Jodele, S.A.1, Myers, K.M.1, Kumar, A.1, Jordan, M.B.1,
Edwards, S.L.1, Kennedy, R.1, Wilhelm, J.1, Painter, W.2,
Anderson, M.2, Filipovich, A.H.1, Davies, S.M.1 1Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH; 2Chimerix, Inc., Durham, NC
Background: Adenovirus infection is a serious and often fatal com-
plication in immunocompromised patients. There are currently no
FDA-approved therapies for adenovirus infection. Cidofovir has
been reported to have variable efficacy in treating Adenovirus but
is associated with significant toxicity, especially renal and possible
marrow toxicity. CMX001 is an oral Lipid -Antiviral-Conjugate
that generates high intracellular levels of the active cidofovir-diphos-
phate without evidence of cidofovir-like nephrotoxicity. CMX001 is
under investigation for the prevention of adenovirus disease.
Methods: We report on 5 patients with adenovirus disease treated
with CMX001. Data were available for . 4 weeks of treatment.
The median age was 1.9 years (Range 1.5 -11.8). The preparative
regimen for the transplant patients consisted of Alemtuzumab, Flu-
darabine and Melaphalan. The graft source was bone marrow.Table 1. Patient Characteristics
Patient Diagnosis
Days post HSCT
of ADV detection
Sites of ADV
infection
Viral Load
(copies/ml)
1 SCID N/A Blood and Stool 770 million
2 SCID due to
RAG2 mutation
-7 Blood and Stool 1.2 million
3 FHL 300 Blood, Stool and
Nasal Secretions
32,000
4 XLP/MDS 70 Blood and Stool 89,000
5 XLP 5 Blood and Stool 102,000
SCID: Severe Combined Immunodeficiency; FHL: Familial Hemophagocytic Lym
phoproliferative Disorder; BIW: twice a week; QW: weekly; TMA: ThrombotGVHD prophylaxis was cyclosporine and methylprednisolone.
Virologic response (VR) was defined as 99% drop from baseline or
undetectable adenovirus DNA by PCR in plasma. Patient character-
istics are shown in Table 1.
Results: Adenovirus disease was diagnosed at a median of 38 days
(range -7 to 300) after transplantation. All patients received intrave-
nous cidofovir for a median of 27 days (range 22-47) prior to starting
CMX001. Four of five patients (80%) had a. 1 log drop in viral load
at the end of 1 week of therapy. VRwas seen in all patients with ame-
dian time to achieve VR was 2 weeks (range 1-3). Four patients re-
ceived doses exceeding those currently being studied. No adverse
events felt to secondary to CMX001 were seen with the 4 mg/kg/
doses. Two patients developed diarrhea that was likely related to
CMX001 therapy while receiving the 2 mg/kg/dose twice weekly.
Both patients had resolution of the symptoms when CMX001 was
stopped and were able to resume therapy without recurrence of
symptoms. No other significant side effects were observed.
Discussion: Our data demonstrates that CMX001 has efficacy
against adenoviral infections with a favorable safety profile. In this
critically ill group of patients, morbidity was high which may reflect
that CMX001 is an investigational medicine and was not used as first
line therapy for adenoviral infections in our institution for these pa-
tients. Clinicians caring for immunocompromised individuals with
adenovirus infections should consider early use of CMX001 for se-
vere adenovirus infections.297
PREVALENCE OF VIRAL INFECTIONS IN CHILDREN UNDERGOING FIRST
ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: TWO
YEAR SINGLE CENTER EXPERIENCE
Ozdemir, N., Jodele, S., Myers, K.C., Mehta, P.A., Bleesing, J.J.,
Jordan, M.B., Marsch, R.A., Kumar, A.R., Bellman, D.,
Filipovich, A.H., Davies, S.M., Grimley,M.S. Cincinnati Children’s Hos-
pital Medical Center, Cincinnati, OH
Background: Viral infections are a major cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (HSCT).With the introduction of newer condition-
ing regimens, increasing use of reduced intensity protocols and T
cell depletion, the risk of post-transplant viral infections may be in-
creasing and specific high risk groups may need to be identified as
candidates for intensive viral monitoring and pre-emptive strategies.
Here we report our experience of viral infections in children under-
going their first allogenic HSCT from January 2009-December
2010.
Methods: One hundred twenty four patients, median age 4.9 years
(range: 0.2-25.4) were identified and charts retrospectively reviewed.
Ninety-five patients underwent HSCT for non-malignant disease,
29 for malignant disease. Graft source was unrelated donor in 102
(82%) and matched related in 22 (18%). Stem cell source was bone
marrow in 94 (76%), peripheral blood stem cells in 16 (13%) and
cord blood in 14 (11%). Sixty-four patients (35 with non-malignant
disease, 29 with malignant disease) received myeloablative condi-
tioning regimens. Forty-six patients (all with non-malignant disease)Dose of CMX001
Adverse
Events
Current Status/Followup
(months)
4 mg/kg/dose BIW None Died of Disseminated
Aspergillosis infection
4 mg/kg/dose BIW None Alive and Well/ 8 months
1 dose of 4 mg/kg/dose BIW then
11 doses of 2 mg/kg/dose BIW
Diarrhea Died of Progressive
Bronchiolitis Obliterans
5 doses of 4 mg/kg/dose BIW
then 32 doses of 2 mg/kg/dose BIW
Diarrhea Alive and Well/7 months
2 mg/kg/dose BIW None Died of Pulmonary TMA
phohistiocytosis; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lym-
ic Microangiopathy.
